Elon Musk Bashes This Media Outlet Over Sam Bankman-Fried Coverage: ‘Giving Foot Massages To A Criminal’

Twitter's owner and CEO Elon Musk voiced criticism of a Wall Street Journal report on FTX's founder Sam Bankman-Fried. What Happened: Musk reacted to a tweet from WSJ Markets which shared a report titled "Sam Bankman-Fried's Plans to Save the World Went Down in Flames."

Twitter’s owner and CEO Elon Musk voiced criticism of a Wall Street Journal report on FTX’s founder Sam Bankman-Fried.

What Happened: Musk reacted to a tweet from WSJ Markets which shared a report titled “Sam Bankman-Fried’s Plans to Save the World Went Down in Flames.”

The billionaire said, “WSJ giving foot massages to a criminal.”

MicroStrategy Incorporated (NASDAQ:MSTR) Chair Michael Saylor also chimed in on the same thread and said Bankman-Fried “counterfeited billions in tokens via securities fraud.”

He said that Bankman-Fried “seized billions from customers via banking fraud, corrupted the establishment with the dirty money, then panic sold billions” in stolen Bitcoin (CRYPTO: BTC) to crash the market.

See Also: Best Technology Stocks Right Now 

Why It Matters: This week, Musk denied another media report which said that Bankman-Fried still owned a $100 million stake in Twitter.

The coverage of Bankman-Fried and his company by The New York Times was earlier panned by Edward Snowden who said, “Justice is Blind” in response.

Meanwhile, Bankman-Fried said Thursday he will appear at the New York Times Dealbook summit on Nov. 30 and will be interviewed by Times columnist Andrew Ross Sorkin.

Read Next: Elon Musk Says Making Internal Twitter Conversations On Hunter Biden Laptop Story Public ‘Necessary To Restore Trust’

Photo courtesy: NASA Kennedy on Flickr

Total
0
Shares
Related Posts
Read More

Turning Point Therapeutics Early Saturday Highlighted Presentation Of Early Clinical Data For Repotrectinib From Care Study In Pediatric, Young Adult Patients At International Society of Paediatric Oncology Meeting

Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations Repotrectinib Demonstrated Confirmed Responses in 3 of 4

TPTX